BRAF and Langerhans cell histiocytosis: In LCH, for example, more than 50% of cases are identified with BRAF mutation [20], and approximately 30% of BRAF wild-type LCH with MAP2K1 mutation [64], but the prevalence of additional malignancies (32%) is lower than that of genome mutations.